ArticleJournal of Alzheimer's disease : JAD2020
Computational Modeling of Catecholamines Dysfunction in Alzheimer's Disease at Pre-Plaque Stage.
Article in Journal of Alzheimer's disease : JAD, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Norepinephrine and dopamine Imbalance in the medial frontal gyrus from patients with Alzheimer's disease.IBRO neuroscience reports · 2026Article
- Explainable machine learning identifies candidate shared neuroanatomical features in Alzheimer's and Parkinson's via importance inversion transfer.bioRxiv : the preprint server for biology · 2026Article
- AI-driven framework for accurate detection of Alzheimer's disease in EEG.Scientific reports · 2026Article
- Polydopamine nanoparticles restore cognition via targeted dopamine delivery and septo-hippocampal cholinergic activation.Theranostics · 2026Article
- Yoga for Neurodegenerative Disorders: Therapeutic Effects, Mechanisms, and Applications in Alzheimer's and Parkinson's Disease.Sports (Basel, Switzerland) · 2025Review
- Modeling Alzheimer's Disease: A Review of Gene-Modified and Induced Animal Models, Complex Cell Culture Models, and Computational Modeling.Brain sciences · 2025Review
- Meta-Reinforcement Learning reconciles surprise, value, and control in the anterior cingulate cortex.PLoS computational biology · 2025Article
- Therapeutic Options in Alzheimer's Disease: From Classic Acetylcholinesterase Inhibitors to Multi-Target Drugs with Pleiotropic Activity.Life (Basel, Switzerland) · 2024Article
- Simulating combined monoaminergic depletions in a PD animal model through a bio-constrained differential equations system.Frontiers in computational neuroscience · 2024Article
- The Neurodegenerative Elderly Syndrome (NES) hypothesis: Alzheimer and Parkinson are two faces of the same disease.IBRO neuroscience reports · 2022Review
- Upregulation of CaMolecular neurodegeneration · 2022Article
- Nosustrophine: An Epinutraceutical Bioproduct with Effects on DNA Methylation, Histone Acetylation and Sirtuin Expression in Alzheimer's Disease.Pharmaceutics · 2022Article
- A multi-expert ensemble system for predicting Alzheimer transition using clinical features.Brain informatics · 2022Article
- An Automated Approach for the Detection of Alzheimer's Disease From Resting State Electroencephalography.Frontiers in neuroinformatics · 2022Article
- Alzheimer's Disease: Current Perspectives and Advances in Physiological Modeling.Bioengineering (Basel, Switzerland) · 2021Review
- Increasing Serotonin to Reduce Parkinsonian Tremor.Frontiers in systems neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's disease (AD) etiopathogenesis remains partially unexplained. The main conceptual framework used to study AD is the Amyloid Cascade Hypothesis, although the failure of recent clinical experimentation seems to reduce its potential in AD research.
objectiveA possible explanation for the failure of clinical trials is that they are set too late in AD progression. Recent studies suggest that the ventral tegmental area (VTA) degeneration could be one of the first events occurring in AD progression (pre-plaque stage).
methodsHere we investigate this hypothesis through a computational model and computer simulations validated with behavioral and neural data from patients.
resultsWe show that VTA degeneration might lead to system-level adjustments of catecholamine release, triggering a sequence of events leading to relevant clinical and pathological signs of AD. These changes consist first in a midfrontal-driven compensatory hyperactivation of both VTA and locus coeruleus (norepinephrine) followed, with the progression of the VTA impairment, by a downregulation of catecholamine release. These processes could then trigger the neural degeneration at the cortical and hippocampal levels, due to the chronic loss of the neuroprotective role of norepinephrine.
conclusionOur novel hypothesis might contribute to the formulation of a wider system-level view of AD which might help to devise early diagnostic and therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.